More than 80% of all cancer patients die from metastasis, not the actual primary tumour. Metastasis is therefore the real killer.
Cancer is complex, heterogeneous and dynamic. Cancer invades and robs; its innate ability to evade standard detection and their evolutionary nature makes treatment fraught with uncertainty.
For the patient, a cancer treatment journey drains physically, emotionally, mentally and financially. For the oncologist, it may mean questions of possible overtreatment and having to subject patients to frequent, painful biopsies. Over the course of treatment, the cancer can evolve and become resistant.
Therefore the ability to precisely detect these changes facilitates timely diagnosis and staging of the disease; this ability is critical for precise, tailored treatment and proactive monitoring. This is where Circulating Tumour Cells (CTCs) become critically relevant.
Circulating Tumour Cells (CTCs) are extremely rare cells that have detached from solid tumours, travel in the bloodstream and can cause the cancer to spread.
They are considered the seeds in metastasis and can be a clear indication of disease progression.
A blood test, or liquid biopsy that can detect and profile these CTCs presents a quick, non-invasive way to obtain real-time information about the cancer disease status. In combination with other diagnostic methods, doctors may be able to design specific responses to fight the diagnosed cancer.
Combining this insight with the ability to match drugs according to disease mutation and resistance, isolating wholly intact CTCs are the potential gold standard for the detection of cancer metastasis.
All from a simple blood draw
With Clearbridge BioMedics' ClearCell® FX system, oncologists and researchers have a faster, more elegant solution for cell enrichment.
Fully automated and entirely label-free, the ClearCell® FX system empowers doctors through every step of the cancer treatment journey.
Based on the patented microfluidic biochip, CTChip®FR1, the ClearCell® FX system achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer. It even provides the potential for serial real-time treatment monitoring.
Clinicians now have a robust and reproducible non-invasive liquid biopsy to monitor metastasis - bringing us closer to providing timely, tailored treatment for patients.
Researchers will also have a highly sensitive assay for CTC enrichment with a larger dynamic range which enables deeper insights and greater understanding of tumour biology.
The ClearCell® FX System, driven by the ClearCell® CTChip®FR1, is one of the world's first fully automated cell retrieval systems that can enrich wholly intact and viable Circulating Tumour Cells (CTCs) from small amounts of blood in under an hour.
Combined with the high levels of purity, the CTCs are enriched in suspension, that allows for easy integration with downstream molecular analyses and diagnostic assays. Meaning that researchers and clinicians can use these insights to provide timely, tailored treatment options.
The microfluidic biochip captures CTCs based on inertial characteristics such as size and deformity, relative to other blood components, by using Dean Flow Fractionation (DFF). Through the DFF process, the cells are focused within the microfluidic channels of the CTChip® FR1, with larger cells along the inner wall and the smaller cells away from it. This label-free approach ensures effective, continuous and quick separation while retaining cell viability thus lending itself to a myriad of downstream applications.
Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from the National University of Singapore (NUS) and is the first incubatee of Clearbridge Accelerator, a high-technology incubator backed by the Singapore Government's National Research Foundation (NRF).
The ClearCell Systems provide a label-free means of Circulating Tumour Cell (CTC) enrichment, as such, offering a myriad of possibilities for downstream analysis on the output CTCs. Utilising patented award winning microfluidic technologies, Clearbridge BioMedics aims to provide the next generation of non-invasive "liquid biopsy" approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers across Asia, Europe and North America..
Clearbridge BioMedics' mission is to innovate and develop novel medical research tools and diagnostic products using cutting-edge technologies, in order to catalyse medical research and discovery, revolutionise disease management, and advance patient care.
Clearbridge BioMedics believes in bringing clarity to cancer, providing each and every patient with timely, tailored treatment.